Vigil Neuroscience (VIGL) Guggenheim Securities Inaugural Healthcare Innovation Conference summary

Company overview and differentiation

• Focuses on microglia-targeted therapeutics for rare and common neurodegenerative diseases, using a precision-based approach to reduce translational risk.

• Only company with both a fully human monoclonal antibody and a first-in-class small molecule TREM2 agonist, enabling a diversified pipeline.

• Lead antibody asset, Iluzanebart, is in phase II for ALSP, while the small molecule is in phase I for Alzheimer's disease.

• First to generate clinical data supporting TREM2 as a therapeutic target in neurodegeneration.

• Secured a $40 million strategic investment from Sanofi, extending financial runway into 2026.

ALSP program progress and regulatory strategy

• Phase II open-label study in ALSP includes 20 patients across two dose cohorts (20mg and 40mg), with interim data showing slowed disease progression in patients with active disease.

• Natural history study provides critical insights into biomarker and clinical endpoint correlations, supporting the use of MRI as a sensitive biomarker.

• FDA has indicated openness to accelerated approval based on biomarker data, with a focus on MRI and soluble CSF1R as key endpoints.

• Full 12-month data from both dose cohorts expected in the first half of 2025, with disclosure planned after alignment with the FDA.

• Patient advocacy played a role in regulatory discussions, emphasizing the need for shorter, non-placebo-controlled studies.

Market opportunity and disease prevalence

• ALSP prevalence in the US is now estimated at 19,000, double previous estimates, due to new genetic data and improved diagnostic understanding.

• Disease is often underdiagnosed or misdiagnosed as MS, Alzheimer's, or FTD, further supporting a larger addressable market.

• European and UK prevalence estimated at 29,000.